Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition

Lantern Pharma, Inc. (NASDAQ:LTRN) is one of the champion AI penny stocks to bargain close now. On January 20, the FDA granted Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-284 an Orphan Drug Designation (ODD). LP-284 is an investigational small-molecule therapy for treating brushed insubstantial sarcomas.

According to Lantern Pharma, the ODD designation applies successful the United States nether the FDA’s orphan cause program. The programme supports the improvement of treatments for diseases affecting less than 200,000 people. This orphan cause presumption for LP-284 is the 3rd specified designation for this molecule; others are for mantle compartment lymphoma (MCL) successful January 2023 and high-grade B-cell lymphoma (HGBL) successful November 2023. It is besides the sixth wide orphan designation awarded to Lantern Pharma’s objective pipeline.

In a antithetic update, connected January 12, Lantern Pharma established an Artificial Intelligence Center of Excellence and Advanced Agentic Labs successful Bengaluru, India. The goal, said the company, is to industrialize and standard its proprietary RADR AI level for planetary biopharma use.

The institution plans the Bengaluru installation to enactment arsenic a planetary scale-up hub for RADR. It volition usage it arsenic the basal for expanding computational capacity, large-scale information engineering, and improvement of instrumentality learning-ready illness models. This level volition beryllium integrated “more deeply” with pharmaceutical and world partners worldwide, the institution stated.

The RADR level presently integrates hundreds of billions of oncology-focused information points, blase instrumentality learning algorithms, and curated illness models. All of these travel unneurotic to make a strategy that identifies biomarkers, predicts cause response, and designs optimized objective strategies.

Lantern Pharma, Inc. (NASDAQ:LTRN) is simply a clinical-stage biopharmaceutical institution that leverages artificial intelligence, instrumentality learning, and genomics to accelerate oncology cause find and development. Its proprietary RADR AI level analyzes billions of information points to place biomarkers, foretell cause responses, and optimize objective proceedings design.

While we admit the imaginable of LTRN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 13 Best Affordable Tech Stocks to Buy Right Now and 10 Best Affordable Long Term Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.